Timothy M. Block

Timothy M. Block

Auto-generated profile, based on publicly available information

Timothy M. Block

Baruch S. Blumberg Institute, Doylestown, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2017 in Hepatology
Verified
Journal Article
Open access
PDF file
HAHarvey Alter
Harvey Alter
TBTimothy Block
Timothy Block
NBNathaniel Brown
Nathaniel Brown
ABAlan Brownstein
Alan Brownstein
CBCarol Brosgart
Carol Brosgart
Fabien ZoulimFabien Zoulim
Fabien Zoulim

1 October 2018 in Antiviral Research
Verified
Journal Article
Closed access
BMBidisha Mitra
Bidisha Mitra
RTRoshan J. Thapa
Roshan J. Thapa
HGHAITAO GUO
HAITAO GUO
TBTimothy M. Block
Timothy M. Block

29 September 2021 in Annual Review of Virology
Verified
Journal Article
Open access
TBTimothy M. Block
Timothy M. Block
KCKyong-Mi Chang
Kyong-Mi Chang
JGJu-Tao Guo
Ju-Tao Guo
Chronic hepatitis B virus (HBV) infection is the leading cause of liver cirrhosis and hepatocellular carcinoma, estimated to be globally responsible for ∼800,000 deaths annually. Although effective vaccines are available to prevent new HBV infection, treatment of existing chronic hepatitis B (CHB) is limited, as the current standard-of-care antiviral drugs can only suppress viral replication without achieving cure. In 2016, the World Health Organization called for the elimination of viral hepatitis as a global public health threat by 2030. The United States and other nations are working to meet this ambitious goal by developing strategies to cure CHB, as well as prevent HBV transmission. This review considers recent research progress in understanding HBV pathobiology and development of therapeutics for the cure of CHB, which is necessary for elimination of hepatitis B by 2030.

1 July 2016 in Antiviral Research
Verified
Journal Article
Closed access
TBTimothy M. Block
Timothy M. Block
HAHarvey J. Alter
Harvey J. Alter
WLW. Thomas London
W. Thomas London
MBMike Bray
Mike Bray

8 April 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
DTDaniel Traum
Daniel Traum
YWYue Julia Wang
Yue Julia Wang
KSKathleen Schwarz
Kathleen Schwarz
JSJonathan Schug
Jonathan Schug
DWDavid K.H. Wong
David K.H. Wong
KCKyong-Mi Chang
Kyong-Mi Chang
Studies of human hepatitis B virus (HBV) immune pathogenesis are hampered by limited access to liver tissues and technologies for detailed analyses. Here, utilizing imaging mass cytometry (IMC) to simultaneously detect 30 immune, viral, and structural markers in liver biopsies from patients with hepatitis B e antigen + (HBeAg + ) chronic hepatitis B, we provide potentially novel comprehensive visualization, quantitation, and phenotypic characterizations of hepatic adaptive and innate immune subsets that correlated with hepatocellular injury, histological fibrosis, and age. We further show marked correlations between adaptive and innate immune cell frequencies and phenotype, highlighting complex immune interactions within the hepatic microenvironment with relevance to HBV pathogenesis.

1 February 2018 in Antiviral Research
Verified
Journal Article
Open access
TBTimothy M. Block
Timothy M. Block
HAHarvey Alter
Harvey Alter
NBNathaniel Brown
Nathaniel Brown
ABAlan Brownstein
Alan Brownstein
CBCarol Brosgart
Carol Brosgart
KSKirti Shetty
Kirti Shetty
In early 2017, the Hepatitis B Foundation invited 30 experts in the fields of hepatitis B and liver cancer research to identify projects they deemed important to the goal of finding a cure for chronic hepatitis B and D and the diseases with which these viral infections are associated. They were also asked to identify general categories of research and to prioritize sub-project topics within those areas. The experts generally agreed on broadly defined areas of research, but there was usually little difference between the highest and lowest scoring projects; for the most part, all programs described in this document were considered valuable and necessary. An executive summary of this discussion was recently published (Alter et al., Hepatology 2017). The present manuscript reports the areas of research identified by the workshop participants, provides a brief rationale for their selection, and attempts to express differences among the priorities assigned to each area of research, when such distinctions were expressed.